Craig Morgan outlines why comparator trials are useful and provides points to consider to ensure the best outcome.
Johnson & Johnson (J&J) has announced that Fortive Corp has made an offer of about $2.7 billion in cash for its Advanced Sterilisation Products (ASP) business.
The FDA has approved Genentech’s Rituxan (rituximab) for use in adults with moderate-to-severe pemphigus vulgaris (PV), making it the first treatment for the condition in more than 60 years.
Apple has announced that it will open up its Health Records application programming interface (API) to developers and researchers this autumn so that they can create an ecosystem of apps that use health record data to better manage medications, nutrition plans and diagnosed diseases.
Following its acquisition of Shire’s oncology business in April, Servier is taking steps to expand its presence in the US and China.
AbbVie has reported positive top-line results for its oral JAK1-selective inhibitor in rheumatoid arthritis (RA), bringing it closer to a potential new early treatment option for patients.
The European Commission (EC) has approved Roche’s Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for post-surgery (adjuvant) treatment of adult patients with HER2-positive early breast cancer (eBC) at high risk of recurrence.
Samsung has partnered with digital healthcare company Babylon to provide access to medical services at the touch of a button for UK users of compatible Galaxy mobile devices.
Bayer and the University of Texas MD Anderson Cancer Center have signed a five-year collaboration agreement to accelerate the development of novel targeted treatments for cancer.
